Socioeconomic benefits of ocrelizumab for multiple sclerosis
- PDF / 167,553 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 80 Downloads / 247 Views
1
Socioeconomic benefits of ocrelizumab for multiple sclerosis Two Roche-funded studies presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research in November 2020, which was held as a virtual conference (Virtual ISPOR Europe 2020), evaluated the socioeconomic benefits of ocrelizumab over a 5-year horizon in patients with multiple sclerosis (MS) in the UK.
Primary progressive MS One study found that treatment with ocrelizumab offers substantial socioeconomic benefits compared with best supportive care (BSC) in patients with primary progressive multiple sclerosis (PPMS).1 A Markov model populated with data from the double-blind ORATORIO trial and its open-label extension was used to assess the socioeconomic benefits of ocrelizumab versus BSC in patients with PPMS. The estimated socioeconomic value of ocrelizumab versus BSC in patients with PPMS totalled £77.2 million* over 5 years, primarily due to cost savings of £33.3 million for informal care, £16.5 million in productivity loses, £14.8 million for community services and £9.1 million for disability support pensions.
Relapsing MS Ocrelizumab was also found to offer substantial socioeconomic benefits compared with three alternative treatments in patients with relapsing forms of multiple sclerosis (RMS).2 A Markov model populated with data from the OPERA trials and a network meta-analysis was used to assess the socioeconomic benefits of ocrelizumab compared with cladarabine, dimethyl fumarate and natalizumab in patients with RMS. The estimated socioeconomic value of ocrelizumab over 5 years totalled £72.2 million versus dimethyl fumarate, including costs savings of £27.9 million for informal care and £23.5 million in productivity losses; £27.9 versus natalizumab, including costs savings of £10.7 million for informal care and £9.2 million in productivity losses; and £18.7 million versus cladribine, including costs savings of £7.2 million for informal care and £6.1 million in productivity losses. * 2019 British pounds 1. Di Maio D, et al. Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Primary Progressive Multiple Sclerosis. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND55, 16 Nov 2020. 2. Di Maio D, et al. Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Relapsing Forms of Multiple Sclerosis. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND47, 16 Nov 2020. 803519781
1173-5503/20/0868-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
PharmacoEconomics & Outcomes News 12 Dec 2020 No. 868
Data Loading...
